Supplemental figure 3 from A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

Supplemental figure 3. Mutation frequencies in pre-and on-treatment plasma samples as determined by next-generation sequencing of cfDNA using the Guardant360 assay.